Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic by Gish, RG & Cooper, SL
Hepatitis B in the Greater San Francisco Bay Area: an
integrated programme to respond to a diverse local epidemic
R.G. Gish
1 and S.L. Cooper
2,3,4,5 1Division of GI Hepatology, University of California, San Diego, CA, USA;
2Division of Hepatology,
San Francisco Center for Liver Disease, San Francisco, CA, USA;
3Department of Medicine;
4Department of Transplantation, California Paciﬁc Medical
Center and Research Institute, and Sutter Paciﬁc Medical Foundation, San Francisco, CA, USA; and
5Liver Immunology Laboratory, California Paciﬁc
Medical Center and Research Institute and Sutter Paciﬁc Medical Foundation, San Francisco, CA, USA
Received January 2010; accepted for publication August 2010
SUMMARY. Although chronic hepatitis B (CHB) affects
approximately 2 million United States residents, there is no
systematic screening of at-risk individuals, and most remain
unaware of their hepatitis B virus (HBV) infection.
Unmonitored and untreated, CHB results in a 25–30% risk
of death from liver cancer and/or cirrhosis, inﬂicting an
increasing healthcare burden in high-prevalence regions.
Despite high prevalence in immigrant Asians and Paciﬁc
Islanders, among whom CHB is a leading cause of death,
community and healthcare provider awareness remains
low. Because safe and effective vaccines and effective
antiviral treatments exist, there is an urgent need for inte-
grated programmes that identify, follow and treat people
with existing CHB, while vaccinating the susceptible. We
describe an extant San Francisco programme that integrates
culturally targeted, population-based, HBV screening, vac-
cination or reassurance, management and research. After
screening over 3000 at-risk individuals, we here review our
operational and practical experience and describe a simple,
rationally designed model that could be successfully used to
greatly improve the current approach to hepatitis B while
ultimately reducing the related healthcare costs, especially
in the high-risk populations, which are currently under-
served.
Keywords: Asians and Paciﬁc Islanders, at-risk populations,
cancer surveillance, chronic hepatitis B, culturally targeted
screening, disease surveillance, hepatitis B virus, hepato-
cellular carcinoma, high-risk populations, screening,
vaccination.
INTRODUCTION
Chronic hepatitis B (CHB) is a major public health problem,
affecting an estimated 400 million people worldwide [1,2],
and at least 1.5–2 million people in the United States (US)
[3]. The Hepatitis B Foundation (HBF) calculates that the US
CHB prevalence is substantially larger than the previously
accepted estimate of 1.25 million, because the highest-risk
populations are under-represented in surveillance studies
that have generally not accounted for the large and ongoing
inﬂux of foreign-born individuals from countries with mod-
erate and high hepatitis B virus (HBV) prevalence (Fig. 1),
and because a large percentage of chronically infected indi-
viduals remain undiagnosed [4]. Using census and current
HBV prevalence data, HBF estimates the current burden of
CHB in the US to be approximately 2 million people.
Despite these high numbers, even in the US there is no
systematic nationwide screening of at-risk individuals, and
most people with CHB remain symptom-free and unaware
that they are infected until a late disease stage when they
develop clinically apparent hepatocellular carcinoma (HCC)
and/or cirrhosis. Without medical monitoring and treat-
ment, the risk of HCC and cirrhosis, with sequelae of liver
transplantation or death, is 25–30% [5–9]. Modelling the
burden of CHB worldwide, the Centers for Disease Control
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620 000 persons died from HBV-related causes, with
580 000 (94%) from CHB-related cirrhosis and HCC [10].
These estimates were almost certainly conservative.
The disease spectrum of CHB is highly variable. At one
extreme, some persons experience inactive infection (no
hepatitis) throughout a lifetime, while at the other some
develop cirrhosis and HCC during childhood. Between
these extremes are many intermediates where there are
irregular cycles of disease activation (ﬂares in hepatic
enzymes with liver inﬂammation, injury and ﬁbrosis) and
dampening. In developed countries, CHB can be effectively
treated with antiviral drugs when individuals have access
to informed healthcare providers and adequate healthcare
coverage.
The acquisition of HBV can largely be prevented. Vertical
transmission from mother to child can be arrested in up to
95% of cases by prompt neonatal vaccination and infusion of
hepatitis B immune globulin (HBIG) [11]. Universal neonatal
HBV vaccination, introduced in the US in 1991, has resulted
in immunity in a high proportion of young children [12].
Horizontal transmission can also be prevented by vaccina-
tion, which is highly effective [13] and unequivocally safe,
although the use of vaccination by at-risk adults remains
disappointing.
Because safe and effective vaccines and therapies exist,
there is an obvious humanitarian need to identify, follow
and, when necessary, treat people with existing CHB, while
also vaccinating their contacts to prevent transmission. For
efﬁcient case identiﬁcation, there is an imperative to sys-
tematize this task by moving towards regional and national
programmes that deploy targeted screening, with no socio-
economic repercussions for people who test positive.
Hepatitis B virus has particularly high prevalence in
Asians and Paciﬁc Islanders (API), most of whom become
chronically infected at birth or in childhood [14]. It is esti-
mated that API constitute more than half of the global res-
ervoir [10]. In recent years, screening programmes in New
York City, Philadelphia, Atlanta, Chicago and California
have reported 10–15% prevalence of CHB among immigrant
API [15–19]. In regions with high API population density,
the management of patients with cirrhosis and HCC will
produce an increasing healthcare burden without prompt,
effective intervention. However, there is still no nationally
coordinated programme that systematically addresses the
identiﬁcation and requirements of Americans living with
CHB, especially in high-prevalence populations. Unfortu-
nately, the National Institutes of Health Consensus Devel-
opment Conference on the management of HBV in October
2008 devoted little attention to screening, liver cancer sur-
veillance, access to healthcare services, or cultural and other
barriers inhibiting awareness, testing, and accrual of
knowledge about the necessity for monitoring and how to
obtain well-informed medical management.
In early 2010, the Institute of Medicine (IOM) released an
in-depth report entitled Hepatitis and Liver Cancer: A National
Strategy for Prevention and Control of Hepatitis B and C [20]
which noted the urgent need to address these diseases and
discussed three major factors currently impeding efforts to
prevent and control them:
• Lack of knowledge and awareness about these diseases
among healthcare and social-service providers.
• Lack of knowledge and awareness about these diseases
among high-risk populations, as well as the general
public and policy-makers.
Fig 1 Geographical distribution of hepatitis B virus (HBV) infection – worldwide, 2006. For multiple countries, estimates of
prevalence of hepatitis B surface antigen (HBsAg), a marker of chronic HBV infection, are based on limited data and might not
reﬂect current prevalence in countries that have implemented childhood hepatitis B vaccination. In addition, HBsAg prev-
alence might vary within countries by subpopulation and locality. Source: Centers for Disease Control and Prevention (CDC)
Travellers health; yellow book. Atlanta, GA: US Department of Health and Human Services, CDC; 2008.
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this problem resulting in inadequate public resources
being devoted to prevention, control and surveillance
programmes.
The IOM report gave detailed recommendations for
improving surveillance, increasing knowledge and aware-
ness among both healthcare practitioners and the public,
improving immunization programmes and expanding viral
hepatitis services. The report detailed major gaps in these
areas with at-risk populations and foreign-born residents.
Noting that nearly half of the US foreign-born population
comes from HBV-endemic countries, a strong recommen-
dation was made for culturally appropriate screening pro-
grammes and related services for this population.
Efforts to address all of these concerns have so far consisted
mainly of relatively small local or regional US programmes
targeting high-risk populations. A recent nationwide survey
identiﬁed only a possible 55 community-based screening and
vaccination programmes in the US, with the majority found
in California (23 programmes) and the mid-Atlantic region
(14 programmes) and the rest scattered through the Midwest
(6 programmes), New England (3 programmes), Hawaii (2
programmes), Texas (2 programmes), Colorado (1 pro-
gramme), Washington (1 programme) and Louisiana (1
programme) [21]. Two programmes did screening in multiple
states. Although the lack of response from 20 programmes
indicates that they may no longer be operational, the
researchers conﬁrmed that 32 of these programmes were
currently screening or had screened within the last year. In
addition to screening and vaccination, 74% of the pro-
grammes provided HBV education and 71% treatment
referrals. Only 29% directly provided HBV treatment.
Two previously established programmes can serve as
examples of projects that have been effective in providing
HBV education and screening. The nonproﬁt Asian Liver
Center (ALC) at Stanford Universitys Jade Ribbon Campaign
(JRC) was established in 2001 to raise awareness and pro-
vide information about HBV and liver cancer to both the API
community and health professionals. The JRC incorporated
access to vaccination but not to treatment. In 2005, the
Asian American Hepatitis B Programme (AAHBP), a col-
laboration of community groups and academic and com-
munity health centres, was launched to provide hepatitis B
screening, vaccination and treatment to the API population
in New York City [18]. AAHBP also provides educational
programmes to increase awareness of HBV infection among
API communities.
In November 2006, San Francisco Resolution 650-06,
proposed by current California State Assemblywoman Fiona
Ma, established the goal of universal HBV screening and
vaccination among the approximately 240 000 API and
other high-risk residents of San Francisco. The San Fran-
cisco Department of Public Health (SFDPH) and the
AsianWeek Foundation (AWF) coordinated this SF Hep B
Free program with major citywide healthcare providers and
community organizations. A steering group comprised of
SFDPH, AWF, and the ALC guided the establishment of a
working group to develop the programme which included
our non-proﬁt San Francisco institutions, the California
Paciﬁc Medical Center (CPMC) and its independent afﬁliate,
the Sutter Paciﬁc Medical Foundation (SPMF). CPMC/SPMF
(CPMC) was asked to play a major role on the basis of
established expertise, infrastructure and history of integra-
tion into the multiethnic San Francisco communities. Major
efforts are now underway by public health departments, the
American Liver Foundation, the CDC, the American Asso-
ciation for the Study of Liver Disease, the HBF, and other
parties to tackle the US HBV burden. The CPMC experience
shows both the highlights and pitfalls of an integrated
approach for detecting, preventing and managing HBV
infection in a US region of high endemicity. The informa-
tion may help reﬁne plans for developing effective regional
HBV healthcare strategies.
OVERALL GOALS OF A CHRONIC HEPATITIS B
INTEGRATED PROGRAMME
An effective, integrated response to hepatitis B in San
Francisco, the Greater Bay Area and northern California
requires increased awareness by healthcare professionals,
policy-makers and the general public about the importance
of targeted screening and testing for infection. Educational
programmes thus need to be directed towards all these
groups, with a particular need for HBV-speciﬁc medical
education directed to healthcare providers, as emphasized by
recent surveys showing that 30–55% would order the
wrong test to screen for HBV infection [22]. The goals of our
citywide and regional programme are to:
• Raise awareness among healthcare providers regarding
those populations (such as API) that are at high risk
for HBV infection and the importance of proactive
testing.
• Increase awareness and knowledge among the general
public and healthcare professionals of the prevalence,
natural history and effective management of CHB.
• Highlight the need for an integrated approach to
management once HBV infection has been identiﬁed,
including:
s Liver cancer surveillance;
s Monitoring for disease activation;
s Treatment of patients who ﬁt current evidence-based
criteria.
• Raise awareness in the community that HBV infection is
preventable through vaccination and, when active, is
treatable with safe, effective antiviral agents.
• Emphasize the need for API to become aware of
screening, vaccination, disease surveillance and treat-
ment programmes and of how to gain access to them.
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e42 R.G. Gish & S.L. Cooper• Identify and deconstruct barriers to screening.
• Increase vaccination rates among those who are
susceptible.
• Correct common misperceptions about HBV infection,
vaccination and treatment.
• Outline speciﬁc areas where additional research is
needed to guide best practices and how this coordinated
programme can add to those research efforts.
SPECIFIC OBJECTIVES OF SCREENING
PROGRAMME
A strategically designed screening programme can sub-
stantially lessen the impact of CHB, especially in a high-risk
immigrant population such as that which exists in the
Greater San Francisco area. CPMCs adult HBV screening
programme focuses on the four interwoven areas of educa-
tion, diagnosis, prevention and treatment with the following
key objectives:
In at-risk persons, to:
• Identify susceptible individuals and implement vaccina-
tion;
• Identify and inform individuals with immunity;
• Identify and manage infected individuals.
To conduct surveillance for:
• Disease activation in individuals whose disease has been
quiescent;
• Primary liver cancer (HCC).
To initiate treatment in appropriately identiﬁed individuals
and survey for:
• Treatment success;
• Treatment failure because of either viral resistance or
lack of compliance.
CHRONIC HEPATITIS B IN SAN FRANCISCO, THE
BAY AREA AND NORTHERN CALIFORNIA
Epidemiology and context of chronic hepatitis B in the San
Francisco Bay Area
Chronic hepatitis B is particularly prevalent in San Fran-
cisco, the Bay Area and northern California and is likely to
remain so because of continuing high immigration from
areas of high HBV endemicity, particularly Asia and the
Paciﬁc Islands (Fig. 1). API comprise approximately 32% of
the population of San Francisco [23], with an estimated 25%
(approximately 60 000 people) born in Asia or the Paciﬁc
Islands. According to a report from the SFDPH and CDC,
84% of individuals with conﬁrmed CHB reported in San
Francisco in 2006 were API, 80% of whom were born
outside the United States [24].
The clinical consequences are clearly apparent. In Cali-
fornia as a whole, HCC is one of the ﬁve most common
cancers in Cambodian, Chinese, Filipino, Hawaiian, Korean,
Laotian, Paciﬁc Islander and Vietnamese men [25]. Com-
mensurately, in the Greater Bay area, HBV-related HCC is a
leading cause of death among API, ranking as the second
leading cause of cancer death among Chinese and Viet-
namese men, the third among all API men and Vietnamese
women, and the fourth among Korean men [26]. The range
probably reﬂects the differential prevalence of CHB in
different API subgroups. CHB and liver cancer rates are, in
fact, among the greatest health disparities between API and
Caucasian Americans, with the incidence of HCC in API men
more than three times higher than in Caucasian men [26].
Despite such alarming statistics, because of low awareness of
risk and paucity of symptoms many individuals do not know
that they are infected. The consequences include increased
risk of transmission, as well as failure to seek monitoring and
treatment, leading to substantially increased risk of disease
progression.
Access to healthcare among the API populations of Cali-
fornia may also be limited. For instance, the town of Merced,
located in the agricultural San Joaquin Valley, is home to
more than 6000 Hmong people [27], a group ancestrally
from southern China [28]. Because of a language barrier,
Hmong individuals experience difﬁculty obtaining health-
care and understanding interactions with healthcare
professionals during screening and physical examinations.
Studies have shown that, in general, Asians who lack ﬂu-
ency in English are less likely to receive adequate preventive
healthcare [29].
Coinfection with HBV and human immunodeﬁciency
virus (HIV) and/or hepatitis C virus (HCV) among API
Americans is less common than HBV monoinfection but in
the Bay Area, HIV and HCV are also highly prevalent.
Coinfected individuals are likely to have higher serum HBV
DNA levels and experience faster progression to cirrhosis
and liver cancer [30]. Accurate rates of coinfection with
HBV are unclear at this time and warrant investigation. In
the CPMC programme, when a person with HBV is iden-
tiﬁed, a medical professional will ask screening questions to
identify those at risk for HIV and HCV, and subsequent
testing will be ordered, if indicated and feasible, depending
upon healthcare coverage. It is important to be aware of
fears about the possible consequences of testing positive in
a private insurance, managed healthcare system, and for
members of the healthcare team to discuss these issues
with patients.
Target populations for hepatitis B screening
Recommendations for HBV screening are based on the
population groups at risk. In addition to API Americans,
other high-risk groups living in San Francisco and the Bay
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include the following [31]:
• Family members of individuals who have HBV infection.
• Individuals born in other areas with intermediate to
high prevalence for HBV infection.
• Pregnant women (currently mandated in California).
• Women with a history of many sexual partners.
• Individuals with history of sexual contact with HBV-
infected persons.
• Individuals who inject drugs.
• Correctional facility inmates.
• Men who have sex with men.
• HIV-infected and/or other immune-compromised indi-
viduals.
• Individuals with chronic liver disease.
• Haemodialysis patients.
Public health response to hepatitis B
San Francisco, the Greater Bay Area and similar regions
require a comprehensive plan for detecting and managing
local HBV infection which implicitly includes provision of
access to healthcare. The task of developing a uniﬁed pro-
gramme is hampered by a series of factors, including social
and cultural diversity between and within the high-risk
populations. A central element of our local public health
plan is a coordinated screening programme directed towards
individuals at greatest risk of HBV infection and transmis-
sion. Those found neither infected nor immune should
undergo vaccination, which we are encouraging and
incentivizing in our CPMC programme by providing free
service and vaccine. In addition, feasible models for the
appropriate management of individuals who are already
infected need to be more effectively developed and imple-
mented.
A public health response to hepatitis B in San Francisco,
the Greater Bay Area and northern California should include
the following components:
• Educational programmes that inform high-risk individ-
uals about screening, vaccination and treatment
options;
• Implementation of culturally sensitive HBV screening
and vaccination programmes in API and other ethnic
communities that would identify individuals with CHB,
help them obtain appropriate management including
cancer surveillance and treatment, and explain the
indications, beneﬁts, risks and side effects associated
with the various medications [16];
• Use of electronic registries by local health departments
and healthcare systems to provide services to individuals
with CHB, including ability to put HBV-infected indi-
viduals in contact with appropriate prevention and care
services.
THE CPMC SCREENING PROGRAMME:
INFRASTRUCTURE, LOGISTICS AND RESULTS
TO DATE
Personnel
As part of the SF Hep B Free initiative, CPMC has committed
to screen at least 10 000 local API at no cost to the subject.
Practical implementation of the CPMC HBV screening pro-
gramme has principally been orchestrated by a coordinator
who is the only salaried member of our programme. Multi-
lingual volunteers including nurses, SPMF research labora-
tory scientists, SPMF Liver Center clinical administrative
personnel, a programme consultant and supervised phle-
botomy students were deployed to staff each screening site.
Certain key personnel, including the programme coordina-
tor, were present for each screening event. A hepatologist
was also present at most events. Full details on screening site
personnel and their duties are available in the supplemen-
tary materials and on our website at: http://www.cpmc.org/
advanced/liver/physicians/default.html.
Funding
Funding for the CPMC HBV screening programme was pro-
vided by unrestricted charitable grants from CPMC Foun-
dation and from Gilead Sciences. Screening tests for hepatitis
B surface antigen (HBsAg) and anti-HBs were performed by
Quest Diagnostics (Madison, New Jersey) under special
contract. Because of cost, we omitted testing for the hepatitis
B core antibody.
Creating awareness and providing education in our
multilingual community
Developing a cost-effective HBV awareness and education
programme for API and their healthcare providers has been
challenging, especially within our budget. The objective of
encouraging testing with appropriate follow-up for API
requiring vaccination, monitoring or management remains
an evolving work in progress. CPMC, in concert with the SF
Hep B Free programme, has coordinated a series of public
notices and education efforts. These efforts have included
banners on buses and bus-stop structures, billboards, infor-
mation published in English and Asian language newspapers,
radio broadcasts and television exposure. In the aggregate,
these have promoted community awareness of the overall
programme, while we focused awareness on speciﬁc issues
via media events, news articles and press releases.
Some of the initial efforts were not cost effective. For
example, early in the CPMC programme the authors
recorded public service announcements (PSAs) broadcast on
local radio stations. The PSAs delivered an educational
message and an appeal to get tested (http://www.cpmc.org/
advanced/liver/physicians/default.html). However, even
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daily for 1 week, cost $10 000 USD, prohibiting this as a
regular medium. Finding local media willing to broadcast
such PSAs at little or no cost would be important for pro-
grammes wishing to use this approach to raising awareness.
Promotional posters have been developed speciﬁcally by
our team and deployed in and around the four main CPMC
campuses in San Francisco, supplemented by campus-wide
e-mailed newsletters. The content delivered awareness and
encouraged testing of at-risk individuals and their family
members. Particularly effective has been the combination of
education and screening events that we have conducted at
higher educational establishments and at venues of natural
congregation within the API community, including com-
munity centres and clinics, churches and restaurants. More
recently, we extended the same strategy to workplaces
employing signiﬁcant numbers of API. Such events have
resulted in approximately 50–100% of attendees being tes-
ted. API street fairs and festivals achieve lower proportional
testing rates but high aggregated numbers, and permit
economically efﬁcient awareness and education opportuni-
ties, including within families. Other ongoing strategies
include high school-based HBV education seminars with
competitions and prizes for students designing the most
innovative and communicative posters.
Cultural alignment of all components of the programme
has been complex. In an effort to tackle this at a basic level
we generated printed materials reﬂecting the major local
Asian languages and recruited voluntary programme
members who are multilingual. On the SF Hep B Free web-
site (http://www.sfhepbfree.org), there are currently links to
very brief videos that explain the importance of screening,
vaccination and treatment in English (http://www.you
tube.com/watch?v=3k-O3DE2HfI&feature=related), Manda-
rin (http://www.youtube.com/watch?v=BKTdMiHvX_U) and
Cantonese (http://www.youtube.com/watch?v=pBny8Wv
DkSA). To improve this aspect of our programme, we are
considering creating additional video presentations in all of
the common Bay area Asian languages which could be made
freely available online. The presentations would provide a
concise overview of the need for screening and the resources
available for this at our locations and those of our city
screening partners. The videos would conclude with a web
address linking to more information in that particular lan-
guage, a link that would take the viewers to the materials we
have already produced. To tackle this more deeply would
probably require more resources than are currently avail-
able. This is an area requiring more research.
More recently, we have been able to minimize media
expenditure as a result of our CPMC programme being con-
ducted in conjunction with the citywide SF Hep B Free initia-
tive. The latter has gradually gained momentum and is now
providing most of the advertising. The programme has de-
ployed culturally attuned newspaper advertisements, posters,
and placards on public transport. In addition, there is now a
contracted marketing organization that helps position news
andpressreleasesthatarelinguisticallyandculturallyfocused
and put forth in a timely fashion before each screening event.
The authors and their specialist colleagues also conduct
CME events for API healthcare providers within CPMC and
throughout the city, although such events typically attract
only low numbers of key individuals. With other physician
members of the medical protocol group of the SF Hep B Free
programme, the authors helped develop a simple ﬂow chart
aimed at promoting appropriate HBV testing by community
API healthcare providers and facilitating test interpretation
and subsequent management decision-making. The ﬂow
chart is available at: http://www.sfhepbfree.org/ﬁles/educa-
tion_clinicians/Flowchart_Diagnostic_revised2009.
pdf. A proposal by us for the California State Medical Board
to mandate that physicians should successfully complete a
basic hepatitis B medical education course as a prerequisite
for license renewal (akin to an earlier pain management
course) failed to gain traction.
Screening results to date
In the ﬁrst 24 months, 3120 people were screened at forty
sites encompassing eight different types of venue. These in-
cluded higher educational establishments with large num-
bers of Asian students (n = 1412 people screened at this type
of site), Asian street festivals and fairs (n = 922), Asian
restaurants (n = 324), churches (n = 35), a community
centre (n = 41), the CPMC hospital campuses (n = 377) and
the CPMC liver clinics (n = 9). The majority of screening
events were held during daytime hours.
Of the 3120 people screened, 2477 (79%) were identiﬁed
as API. We identiﬁed 6% HBV prevalence among 1798
foreign-born (ﬁrst generation) individuals, 2% prevalence
among 365 second-generation API and 0% among third-
generation API, although only 37 of the latter were
screened. The proportion of already immune individuals was
54%, 58% and 43% in each generation, respectively.
Test results automatically deploy into a secure and conﬁ-
dential database purchased from HKS Medical Information
Systems (Omaha, Nebraska, USA) and dedicated solely to the
HBV screening programme. At some screening events in API
communities, fewer than 50% of attendees came forward to
be tested, suggesting a signiﬁcant possibility of sampling
error in our dataset.
Screened individuals have been informed of their test
results, given a simple explanation of the meaning of these
results and advised regarding a course of action using letters
mailed to their stated places of residence. Depending on the
language information provided on their intake form, we have
sent letters in English, Chinese, Vietnamese or Korean, where
appropriate; samples of these letters are available both in the
supplementary materials and at our website: http://
www.cpmc.org/advanced/liver/physicians/default.html. In
addition, telephone calls to every subject who tested HBsAg-
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the consultant and one of the authors (SC), supplementing
the standard letter directed to the patient. Telephone follow-
up has augmented successful contact and response, partic-
ularly among foreign-born individuals who failed to receive,
open or understand the mailed letter. In some cases, we have
been unable to conﬁrm that positively screened subjects have
been made aware of their infection status because of inability
to contact them either directly or indirectly through an
intermediary such as a primary care provider. To date, we
have made personal contact with 73 of 116 (63%) people
who tested HBsAg-positive, and we are continuing to attempt
to follow up with the remaining 43 people.
Thus, to the greatest extent possible within this frame-
work, those already immune to HBV have been informed of
their protected status, and those susceptible to infection have
been offered free vaccination at dedicated clinics. The out-
come of our free vaccination programme is summarized in
Table 1. Only 325 (23%) of the 1410 susceptible API have
returned for vaccination to date. Because vaccination costs
were not a factor, these data emphasize the need for even
more resources to be devoted to a more culturally aligned
education and call-back system to enhance complete follow-
up for a full cycle of HBV vaccination. To this point, 193
(59%) of 325 initial vaccinees have completed the three-shot
vaccination series. In 2010, we attempted to more deeply
incentivize vaccination by charging an upfront fee of
$60.00, which is fully refundable for individuals who com-
plete the vaccination series.
Management of HBV-infected API
The management of API found to be HBV infected (HBsAg+)
has been greatly affected by the presence or absence of
adequate healthcare coverage.
API with healthcare insurance
When healthcare coverage permits, persons newly identiﬁed
with HBV have been offered follow-up consultation and
laboratory testing, as well as HCC surveillance and antiviral
treatment, when appropriate.
API without healthcare insurance
People who test positive for HBsAg but who do not have
medical insurance coverage have posed an obvious problem
in California. Referrals to a local county hospital have
resulted in long delays (more than 1 year in some in-
stances) before achieving access to specialist care, even for
patients with active hepatitis B, exposing intrinsic deﬁ-
ciencies in Californias private insurance, managed care-
based system. Cultural attitudes and educational hurdles
involving both patients and their primary healthcare pro-
viders amplify such healthcare deﬁciencies. In an effort to
address this, all HBsAg+ uninsured patients have been of-
fered free consultation with one of the authors (SC) at
CPMC in which the implications and their options are
discussed. They are also examined for the presence of
clinically signiﬁcant liver disease. As an initial option, they
are offered applications for CPMC and SPMF Charity Care
(two distinct programmes) and are assisted in completing
the respective applications. The Charity Care programmes
pay for a range of further investigations including liver
tests and, when indicated, a sonogram. However, the vi-
rological tests that we consider the standard of care, par-
ticularly the HBV viral load, are assayed at external
commercial laboratories, the costs of which are not covered
by our charity care programmes. When the individual is
able to pay out of pocket, quantitative HBV nucleic acid
testing can be obtained at reduced cost, typically for about
$120 per test.
Patients with elevated transaminases and/or viral loads
are considered eligible for antiviral therapy and possibly for
liver biopsy. For those requiring nucleos(t)ide analogue
(NA) therapy who cannot afford to pay for the medica-
tions, applications have been made to pharmaceutical
company patient assistance programmes which have been
unanimously successful to date. No patients have yet been
discovered with late-stage disease, including HCC, which
would present an even greater challenge. A relatively new
programme operated by the SFDPH called Healthy San
Francisco (http://www.healthysanfrancisco.org/) provides
an eventual avenue for care for the uninsured who reside
in the city of San Francisco. It is available regardless of
immigration status, employment status or preexisting
medical conditions. All residents with an income at or
below 500% of the Federal Poverty Level (in 2010, for one
person $54 150 USD; for a family of four $110 250 USD)
are eligible to enroll in the programme, and fees (both
quarterly participant fees and point-of-service fees) are
based on a sliding scale according to income. The pro-
gramme is intended to make comprehensive healthcare
services within the city of San Francisco accessible and
affordable to all uninsured residents. In practice, some
patients with active disease have found the programme
difﬁcult to navigate and their access to care has been
stalled for long periods, indicating that reﬁnements will be
necessary. However, as our screening programme expands,
Healthy San Francisco may become an increasingly honed
and valuable resource for patients. In countries with na-
tional healthcare programmes, the rigours of obtaining
Table 1 Free hepatitis B virus vaccination uptake by sus-
ceptible Asians and Paciﬁc Islanders (January 2008 through
December 2009)
Number
screened
Number
susceptible
Number of
vaccinations
x1 x2 x3
3120 1410 325 254 193
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infected citizens.
The major beneﬁts to a screened population are vaccina-
tion of at-risk persons, the possibility of prompt evaluation
and treatment of people with active hepatitis and/or incipi-
ent liver failure, and early identiﬁcation and treatment of
HCC. Currently, however, despite our programme, there is
no system in place that provides timely universal care to all
those who need it. In parallel with this screening pro-
gramme, we are examining cost effectiveness and barriers to
screening and healthcare access. The latter pose signiﬁcant
obstacles to programme success, not only for our programme
but for all programmes with similar goals, particularly in the
absence of a national healthcare programme.
Ultimately, the impact of implementing widespread
screening strategies if a large number of patients do not have
care or medication coverage is a fundamental question that
extends beyond this manuscript and probes the core of the
current healthcare debate in the United States. Is it ethical to
screen for hepatitis B when a signiﬁcant proportion of those
affected do not have access to modern standards of care? We
argue that hepatitis B satisﬁes criteria adopted by the World
Health Organization for implementation of a screening pro-
gramme [32]. We propose that identifying the extent of the
hepatitis B problem and the associated clinical need may
provide the most compelling case for healthcare provision
and reform. In the interim, we are deploying the measures
already discussed to provide care and to assist with medi-
cation coverage.
Research
There are deﬁciencies in the evidence quantifying the true
burden and natural history of hepatitis B in the US immi-
grant population. Using data from the screening pro-
grammes, a long-term follow-up programme carried out by
CPMC in conjunction with city healthcare partners and
SFDPH will begin tackling this. Adjunctively, molecular
epidemiological studies will attempt to correlate the
natural history of hepatitis B in this region of the US
compared with the country of origin. These data will
contribute substantially to the base of knowledge, particu-
larly as there is a current dearth of information deriving
from population studies in immigrants living in contempo-
rary America.
Possible challenges for similar programmes
We have identiﬁed certain obstacles that may present chal-
lenges in other areas seeking to establish similar screening
programmes.
• First and foremost, our CPMC programme has had the
considerable political and practical support and backing
provided by the City of San Franciscos legislation,
discussed earlier, that established the goal of imple-
menting universal screening and vaccination for HBV
infection among API and other high-risk residents. In
addition, we were working as part of the SFDPHs SF
Hep B Free programme. In other areas, particularly
those where there is less awareness of the extent of HBV
infection and the need for screening and treatment, such
support may be lacking.
• As already mentioned, promotion of awareness about
the need for screening and the existence of a screening
programme can be costly. The CPMC programme had
the advantage of the promotional efforts provided by the
SF Hep B Free programme. In areas without similar
initiatives, the full cost would be borne by the screening
programme.
• In any given region, it will be necessary to identify the
languages most commonly spoken so that materials in
those languages can be obtained and made available.
The CPMC programme will make materials it has
developed freely available. However, in some areas
there may be a need for materials in languages other
than those commonly spoken in San Francisco, putting
the burden on that communitys programme of devel-
oping materials in additional languages.
• Our programme has relied heavily on volunteers,
including a consultant, multilingual nurses, phlebotomy
students and hepatologists willing to donate their time.
Finding volunteers who have the necessary skills and
are willing to donate their services repeatedly over time
may be problematic.
• Our programme was only made possible through char-
itable grants that provided funding for a salaried
programme coordinator and other expenses. Lacking a
national health programme that would pay for screen-
ing services, the ﬁrst step in other US communities may
be to seek grants that will provide funding. In wealthy
countries such as the US, we believe that reliance on
grant funding for important healthcare initiatives is
unnecessarily brittle.
• As discussed earlier, postscreening follow-up in line with
modern standards of care, particularly for the unin-
sured, is vital. In regions lacking the type of charity care
programmes in place at CPMC, or the type of citywide
programme embodied in Healthy San Francisco, this may
pose the largest obstacle.
• Last but not least, regions of relatively low HBV
prevalence will require even more highly targeted
programs of this type to maximize utility and cost
effectiveness. Similar initiatives will be required. We
anticipate, however, that such programs are justiﬁed
and will remain cost effective owing to mitigating the
substantial costs associated with managing the fre-
quently serious complications in patients whose HBV
has been unidentiﬁed.
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The prevalence of HBV infection and related liver disease is
increasing among API and other high-risk ethnicities in San
Francisco, the Bay Area and similar US regions, primarily due
to ongoing immigration from parts of the world where HBV is
endemic. This creates the need for a coordinated plan of
activities to reduce the impact on individuals already infected
and to screen and identify individuals at increased risk of
contracting HBV infection. Components of this coordinated
plan would include prevention and education, screening and
diagnosis, treatment and support, surveillance and research.
Prevention and education
Hepatitis B virus transmission is preventable. The availability
of hepatitis B vaccine led to an apparent 67% decrease in the
incidence of acute HBV infection in the US between 1990 and
2000 [33]. The trend has continued, with data collected
through 2006 showing that the incidence of acute hepatitis B
declined by 81% to the lowest rate ever recorded (1.6 cases
per 100 000 population) [34]. Declines occurred among all
agegroupsbutweregreatest amongchildrenundertheageof
15 (98% decline), a clear result of the recommendation and
implementation of universal vaccination of children against
hepatitis B. However, in adults the rate of new infections
remained high, particularly among males aged 25–44 years.
An estimated 46 000 new infections occurred in the US in
2006 and 43 000 in 2007 [35]. In the northern California
region,thisistheresultofincreasedimmigration,particularly
among API, as well as of other factors including high-risk
sexual behaviour, injection drug use and tattooing, combined
with historically limited HBV screening and education plans.
Priority action areas targeted to API communities and
other high-risk populations should include:
• Increased awareness of hepatitis B, including risk factors
for transmission and measures for prevention;
• Increased awareness of the spectrum of risks related to
HBV infection;
• Development of hepatitis B education and prevention
strategies that are ethnicity, culture and group speciﬁc,
including education that speciﬁcally targets cultural
stigma and misconceptions surrounding HBV infection;
• Development of systematic programmes for HBV screen-
ing, vaccination and management;
• State-mandated training of physicians and other health-
care practitioners to provide (and permit) standards of
care, education and counselling to individuals with and
at risk for hepatitis B.
Screening and diagnosis
A number of factors contribute to the low level of screening
for and diagnosis of HBV infection:
• Unavailability of free or low-cost testing at community
and healthcare centres;
• Lack of awareness among primary care healthcare
providers of:
s The prevalence and implications of HBV infection in
the API population;
s How to test for HBV and how to monitor those who
are infected;
s Asymptomatic status and normal liver tests among
many persons who were infected at birth or during
early childhood;
• Lack of understanding among at-risk individuals that
HBV testing is not typically conducted routinely, and
that the diagnosis can only be made when speciﬁc blood
tests are conducted;
• Fear among API regarding the societal and healthcare
implications of an ofﬁcially recorded positive diagnosis.
The availability and accessibility of screening programmes
are crucial for the diagnosis of HBV infection. There is a need
to expand testing and counselling services, especially within
API communities. Information regarding sites and locations
for testing and vaccination should be provided in API news-
papers and magazines and by local community organizations
assomeindividualsmayhavelanguagebarriers.Multilingual
forms and educational materials are essential. Programmes
should also identify community leaders within at-risk popu-
lations who are ﬂuent in multiple languages and can convey
the requisite information in a trustworthy manner.
Treatment and support
Several factors contribute to a low level of commitment to
treat active HBV infection:
• Individuals with hepatitis B often have no symptoms
and may have normal (or apparently normal) liver
enzyme tests;
• Individuals have little or no appreciation for the poten-
tially serious implications of untreated HBV infection;
• Individuals with hepatitis B and/or their physicians may
be unaware that there are effective and safe treatment
options;
• Individuals may be unable to afford available treatments
or at least perceive them as unaffordable;
• Many individuals are not appropriately educated about
the medication(s) they are taking and the importance of
long-term adherence.
Severalactionsarerequiredtoimproveandsupporttreatment:
• Establish hepatitis B clinics within API communities;
• Ensure adequate training of physicians and other care
providers, particularly those with at-risk or HBV-
infected patients;
• Incentivize physicians to test for HBV in at-risk groups;
as an example, the SF Hep B Free campaign generated
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to engender public conﬁdence in their hepatitis B care by
those clinicians who are listed; both the current Clini-
cians Honor Roll and the Honor Roll Pledge Form are
available at: http://www.sfhepbfree.org/clinicians.
• Support primary care physicians with information on
hepatitis B therapies;
• Utilize or develop educational materials for API and
other at-risk groups regarding available treatments for
active hepatitis B, including information on effective-
ness, side effects and the importance of adherence;
• Provide free or low-cost vaccination for family members,
partners and those at risk through community clinics,
local hospitals and health fairs.
Screening and surveillance
Key actions for hepatitis B screening and surveillance
include:
• Development of culturally sensitive screening and sur-
veillance strategies for:
s API Americans;
s Other high-risk populations;
• Administration of local screening and vaccination pro-
grammes;
• Establishment of conﬁdential local hepatitis B databases
to track and follow up with individuals who test positive
for HBV on screening;
• Prevention of any form of penalty for testing positive.
Research
An evidence base for an effective public health response to
the local hepatitis B epidemic needs to be established
through well-conducted research in regions such as San
Francisco, the Bay Area and northern California. There is a
need to dedicate public research funds to hepatitis B and to
increase local research strategies in the areas of hepatitis B
prevention, surveillance, treatment and pathogenesis. Pri-
mary action areas for research include:
• Local funding for strategic epidemiological research,
particularly to better understand the patterns of HBV
transmission, the impact of prevention strategies and
the extent of liver disease burden in API American
communities;
• Socioeconomic, cultural and behavioural research
within API communities to identify and better under-
stand barriers to screening and treatment;
• Basic scientiﬁc and translational research to better
understand the pathogenesis of disease caused by
HBV. These activities include:
• Study and correlation of HBV genetic factors with the
outcome of HBV infection;
• HBV genotype information:
i. Distribution and partitioning of genotypes and
subgenotypes in different populations;
ii. Examination of viral mosaicism:
a) Identiﬁcation of factors that lead to foster
and amplify recombinant strains.
iii. Comparison of substitution rates in the pre-S
regions.
iv. Correlation of i-iii with liver disease activation
and liver cancer.
v. Treatment outcome/drug resistance rates.
s Core and precore substitution analysis in HBeAg+
cases:
i. Correlation with natural history and treatment
outcomes.
s RT/POL substitution analysis:
i. Frequency in treatment-naı ¨ve cases and the
effect on treatment-induced viral response kinet-
ics and resistance rates.
s Host genetic and immunological factors and the
outcome of hepatitis B:
i. A comparison of immunogenetic polymorphisms
in individuals with different outcomes.
ii. A study of immune responses during respective
phases of disease activation.
s Factors inﬂuencing liver cancer:
i. Race and gender.
ii. HBV genetic analyses.
iii. Host oncogene and tumour suppressor gene
analyses.
iv. DNA and protein adduct measurement to exam-
ine the exposure to genotoxic and carcinogenic
substances.
v. HBV-associated liver cancer biomarker assess-
ment, validation and development.
• Establishment of a pretreatment and on-treatment
biorepository for research purposes, including assess-
ment of the prevalence and mechanism of anti-HBV
drug resistance.
• Establishment of a conﬁdential database to track the
clinical and molecular trajectories of individuals with
hepatitis B.
CALL TO ACTION
The need for an integrated approach to CHB is abundantly
clear. We believe that policy-makers, researchers, educators,
healthcare professionals, awareness and treatment activists
and community members should expeditiously accept this
call to action:
• To develop and implement a targeted strategy for the
increased awareness, prevention, control and medical
management of hepatitis B in high-risk populations.
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early detection, vaccination and preventive education
and training for at-risk individuals and their primary
healthcare providers.
• To develop local and community-based hepatitis B
testing programmes to screen high-risk populations, to
provide information and education and to promote HBV
testing and behaviour modiﬁcation.
• To make testing and vaccination available to all adults
and foreign-born adolescents, especially those from
high-risk populations and ensure continuation of
universal vaccination of children and adolescents.
• To provide educational programmes on hepatitis B to
community-based healthcare providers, especially those
who are responsible for the care of large populations of
API Americans.
• To initiate community-based research programmes to
evaluate best practices for hepatitis B prevention.
This landmark San Francisco HBV screening, vaccination
andmanagement programmewillpromote notonlylocaland
regional but also national and international awareness and
can set targets for other cities in the US and potentially
elsewhere. The proposed opportunistic translational research
will similarly form a hub of interest for hepatologists and HBV
researchers throughout the US and around the globe. The
combined results of this type of integrated approach to CHB
may signiﬁcantly help to turn the tide against this disease,
preventing infection, improving the lives of affected individ-
uals and greatly reducing the associated healthcare burden.
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